Patents by Inventor Klaus Baek Simonsen

Klaus Baek Simonsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors
    Patent number: 9993477
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: June 12, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • PDE9 inhibitors with imidazo triazinone backbone
    Patent number: 9850249
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 26, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS
    Publication number: 20170173018
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: March 8, 2017
    Publication date: June 22, 2017
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
    Patent number: 9643970
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: May 9, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Baek Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgard, Kate Wen, Yazhou Wang
  • PDE9 inhibitors with imidazo triazinone backbone
    Patent number: 9533992
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 3, 2017
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • PDE9 inhibitors with imidazo triazinone backbone
    Patent number: 9434733
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: September 6, 2016
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • PDE9 Inhibitors with Imidazo Triazinone Backbone
    Publication number: 20160213674
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: April 4, 2016
    Publication date: July 28, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • PDE9i with imidazo pyrazinone backbone
    Publication number: 20150274736
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: October 9, 2012
    Publication date: October 1, 2015
    Inventors: Niels Svenstrup, Klaus Baek Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgard, Kate Wen, Yazhou Wang
  • PDE9 inhibitors with imidazo triazinone backbone
    Publication number: 20150045348
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: January 25, 2013
    Publication date: February 12, 2015
    Applicant: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgärd, Kate Wen, Yazhou Wang
  • Azaisoquinolinone derivatives as NK3 antagonists
    Publication number: 20130190499
    Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Application
    Filed: March 11, 2011
    Publication date: July 25, 2013
    Applicant: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Klaus Bæk Simonsen, Søren Møller Nielsen, Karsten Juhl
  • Isoquinolinone derivatives as NK3 antagonists
    Patent number: 8420667
    Abstract: Isoquinolone derivatives of the general formula Ik? are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: April 16, 2013
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Soren Moller Nielsen, Klaus Baek Simonsen
  • Isoquinolinone derivatives as NK3 antagonists
    Patent number: 8415356
    Abstract: Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 9, 2013
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Søren Møller Nielsen, Klaus Bæk Simonsen
  • Isoquinolinone derivatives as NK3 antagonists
    Patent number: 8415373
    Abstract: Isoquinolone derivatives of the general formula (I) are NK3 antagonists.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 9, 2013
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Soren Moller Nielsen, Klaus Baek Simonsen
  • Isoquinolinone derivatives as NK3 antagonists
    Patent number: 8242134
    Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: August 14, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Soren Moller Nielsen, Klaus Baek Simonsen
  • Isoquinolinone derivatives as NK3 antagonists
    Patent number: 8173639
    Abstract: Isoquinolone derivatives of the general formula are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: May 8, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Baek Simonsen, Jan Kehler, Karsten Juhl, Nikolay Khanzhin, Soren Moller Nielsen
  • ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS
    Publication number: 20110288120
    Abstract: Isoquinolone derivatives of the general formula (I) are NK3 antagonists.
    Type: Application
    Filed: October 16, 2009
    Publication date: November 24, 2011
    Applicant: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Soren Moller Nielsen, Klaus Baek Simonsen
  • AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS
    Publication number: 20110224247
    Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Nikolay Khanzhin, Klaus Bæk Simonsen, Søren Møller Nielsen, Karsten Juhl
  • ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS
    Publication number: 20110130420
    Abstract: Isoquinolone derivatives of the general formula Ik? are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Application
    Filed: April 22, 2009
    Publication date: June 2, 2011
    Inventors: Nikolay Khanzhin, Karsten Juhl, Soren Moller Nielsen, Klaus Baek Simonsen
  • ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS
    Publication number: 20110130407
    Abstract: Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Application
    Filed: June 19, 2009
    Publication date: June 2, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Søren Møller Nielsen, Klaus Baek Simonsen
  • ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS
    Publication number: 20100076016
    Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 25, 2010
    Applicant: H. LUNDBECK A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Soren Moller Nielsen, Klaus Baek Simonsen